MedTrace Logo

Bioequivalence of Two Formulations of Acyclovir

NCT02255734 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2014-10-03

No results posted yet for this study

Summary

Bioequivalence of two formulations of Acyclovir (Acyclovir Lyophilized I.V. infusion 250mg) after Intravenous Infusion in Healthy Volunteers.

Conditions

  • Healthy

Interventions

DRUG

Acyclovir

Sponsors & Collaborators

  • Yung Shin Pharm. Ind. Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Po-Yen Chen, M.D. · Taichung Veterans General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-04-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02255734 on ClinicalTrials.gov